| pubmed-article:7935029 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0043210 | lld:lifeskim |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0033306 | lld:lifeskim |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0014938 | lld:lifeskim |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0021665 | lld:lifeskim |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0232970 | lld:lifeskim |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:7935029 | lifeskim:mentions | umls-concept:C0439611 | lld:lifeskim |
| pubmed-article:7935029 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7935029 | pubmed:dateCreated | 1994-11-4 | lld:pubmed |
| pubmed-article:7935029 | pubmed:abstractText | Oral oestrogen treatment in postmenopausal women causes a decrease of insulin-like growth factor I (IGF-I) serum level, probably through a hepatocellular effect. To explore the possibility that the androgenic progestogens oppose this effect, serum IGF-I and sex hormone binding globulin (SHBG) were evaluated in two groups of patients treated respectively with oral conjugated oestrogens (oCE) or transdermal oestradiol (tdE2), in a first phase with the addition of dydrogesterone (DYDR), a non-androgenic progestogen, and subsequently with the addition of norethisterone acetate (NETA). With respect to basal values, treatment with oCE+DYDR caused an increase of SHBG (P < 0.002) and a decrease of IGF-I serum levels (P < 0.05); the shift to NETA addition opposed both effects: SHBG levels decreased partially but significantly (P < 0.01 vs. oCE + DYDR) and IGF-I returned to basal values with a significant increase with respect to the oCE + DYDR phase (P < 0.02). No changes were observed in the tdE2 + DYDR treated women; in this group the shift to NETA addition caused a significant decrease of SHBG values (P < 0.001 vs. before treatment and vs. tdE2 + DYDR phase) and a slight increase of IGF-I values. These differential effects on IGF-I and SHBG serum levels might be relevant as far as breast cancer risk is concerned. | lld:pubmed |
| pubmed-article:7935029 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7935029 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7935029 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7935029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7935029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7935029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7935029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7935029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7935029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7935029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7935029 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7935029 | pubmed:month | May | lld:pubmed |
| pubmed-article:7935029 | pubmed:issn | 0378-5122 | lld:pubmed |
| pubmed-article:7935029 | pubmed:author | pubmed-author:PerinFF | lld:pubmed |
| pubmed-article:7935029 | pubmed:author | pubmed-author:CampagnoliCC | lld:pubmed |
| pubmed-article:7935029 | pubmed:author | pubmed-author:SismondiPP | lld:pubmed |
| pubmed-article:7935029 | pubmed:author | pubmed-author:LanzaM GMG | lld:pubmed |
| pubmed-article:7935029 | pubmed:author | pubmed-author:BigliaNN | lld:pubmed |
| pubmed-article:7935029 | pubmed:author | pubmed-author:LeschKK | lld:pubmed |
| pubmed-article:7935029 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7935029 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:7935029 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7935029 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7935029 | pubmed:pagination | 25-31 | lld:pubmed |
| pubmed-article:7935029 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:meshHeading | pubmed-meshheading:7935029-... | lld:pubmed |
| pubmed-article:7935029 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7935029 | pubmed:articleTitle | Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. | lld:pubmed |
| pubmed-article:7935029 | pubmed:affiliation | Department of Endocrinologic Gynaecology, St. Anna Hospital, Turin, Italy. | lld:pubmed |
| pubmed-article:7935029 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7935029 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7935029 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7935029 | lld:pubmed |
